Comparison of Mortality and Frequency of Red Blood Cell Allo-immunization in Recipients of Leukoreduced and Non-leukoreduced Whole Blood Transfusion in Uganda
- Conditions
- CancerHaematological Disorders
- Registration Number
- PACTR202302787440132
- Lead Sponsor
- ganda Cancer Institute ADB project
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 278
i.Patients admitted to adult ward in the Uganda Cancer Institute or Mulago hospital medical wards (aged 15 years and above)
ii.Patients requiring blood transfusion
iii.Patients who have provided a written informed consent/assent
iv.Negative red blood cell allo-antibody test results at baseline
1.Participation in a competing study
2.Blood transfusion required within 30 minutes preventing the performance of pre-enrollment study procedures.
3.Blood or platelets products transfused in the previous 48 hours before study enrollment
4.Absence of compatible blood units at the time of enrollment
5.Previously enrolled in the same study
6.Failure to obtain pre-transfusion blood sample for testing.
7.Patients with altered mental status or comatose
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mortality
- Secondary Outcome Measures
Name Time Method Prevalence and incidence of RBC alloimmunization